Arrhythmogenic Right Ventricular Cardiomyopathy in Boxers

Crystal D. Hariu, DVM
Texas A & M University

Dewey Carpenter, DVM, DACVIM (Cardiology)
Coral Springs Animal Hospital
Coral Springs, Florida

Abstract: Arrhythmogenic right ventricular cardiomyopathy, formerly termed boxer cardiomyopathy, is a familial primary myocardial disease that is prevalent in boxers. Unique histopathologic changes in the myocardium lead to conduction abnormalities that typically manifest as ventricular tachyarrhythmias with left bundle branch block morphology. Affected dogs can be asymptomatic or may have syncope and/or exercise intolerance. Diagnosis can be difficult, and indications for antiarrhythmic therapy are not always clear. A small number of dogs present with systolic dysfunction and/or congestive heart failure. Screening in asymptomatic breeding dogs was difficult until the recent development of genetic testing.

Harpster was the first to describe a primary myocardial disease in the boxer breed. It is considered a degenerative myocardial disease that is characterized by fatty or fibrofatty infiltration of the right, and sometimes left, ventricle. Formerly termed boxer cardiomyopathy, the disease is now referred to as arrhythmogenic right ventricular cardiomyopathy (ARVC) due to similarities between the disease in boxers and ARVC in humans, including presentation, genetic etiology, and histopathology. Hallmarks of the disease include ventricular arrhythmias, syncope, and sudden death.

ARVC in boxers is a familial disease inherited as an autosomal dominant trait. Variable penetrance is considered probable based on the variability in clinical presentation. Genetic mutations of the cardiac ryanodine receptor (RyR2) and their effect on the associated stabilizing protein calstabin-2 (FKBP12.6) have been demonstrated in some humans with ARVC. Dysfunction of these proteins leads to disruption of calcium homeostasis, which is critical to normal cardiac contractility and rhythm. Veterinary studies have shown that boxers with ARVC have decreased RyR2 protein expression and a calstabin deficiency in the left ventricle compared with controls. Additionally, mutations of the genes encoding the desmosomal proteins plakophilin-2, plakoglobin, desmoplakin, desmoglein-2, and desmocollin have been demonstrated in some humans with ARVC. Meurs et al did not identify any mutations in these desmosomal genes in ARVC-affected boxers.

Clinical Presentation

ARVC in boxers is typically a disease of adult onset, but the clinical presentation is variable. Harpster originally described three forms: asymptomatic dogs with occasional ventricular premature complexes (VPCs); dogs with episodes of syncope, weakness, or exercise intolerance associated with ventricular tachyarrhythmias; and dogs with tachyarrhythmias, usually ventricular, and some degree of myocardial dysfunction or congestive heart failure (CHF). Additionally, some dogs die suddenly, even with no previous clinical signs.

Diagnosis

Until recently, there was no genetic test to aid in diagnosis. Family history and multiple diagnostic tests are routinely used to aid in diagnosis (BOX 1). In addition to the cardiac-specific diagnostic tests listed in this article, general blood work should be performed to rule out any underlying metabolic cause of arrhythmia (e.g., anemia, hypokalemia, acidosis, hypoxia). Abdominal imaging should also be considered in appropriate cases because abdominal masses (especially splenic) can cause ventricular arrhythmias.

Physical Examination

Many boxers with ARVC have no abnormalities on physical examination, but a tachyarrhythmia may be auscultated, characterized by extrasystolic beats and pulse deficits. A systolic murmur or gallop sound may be auscultated at the
left apex in dogs with the myocardial dysfunction form of ARVC.1,2,18 Left basilar systolic murmurs are common in boxers; these are thought to be physiologic or due to aortic stenosis19,20 and should not be associated with ARVC.

Thoracic Radiography
Thoracic radiography findings are typically normal unless systolic dysfunction or CHF is present.1,2,20 The most common findings in one study of boxers with the myocardial dysfunction form of ARVC were generalized cardiomegaly, left atrial enlargement, pulmonary edema, or pleural effusion.18

Electrocardiography
ARVC is a disease characterized by ventricular arrhythmias1,2; therefore, electrocardiography (ECG) is critical to diagnosis. The most common ventricular arrhythmia in boxers originates in the right ventricle and manifests as VPCs with left bundle branch block morphology, primarily positive deflections of the QRS complexes in leads II, III, and aVF (FIGURE 1).21 VPC complexity varies: VPCs may be seen as single complexes, couplets, or runs of ventricular tachycardia. Supraventricular tachyarrhythmias, such as atrial fibrillation, have also been noted in boxers with the myocardial dysfunction form of ARVC.2,18

Thoracic Radiography
Thoracic radiography findings are typically normal unless systolic dysfunction or CHF is present.1,2,20 The most common findings in one study of boxers with the myocardial dysfunction form of ARVC were generalized cardiomegaly, left atrial enlargement, pulmonary edema, or pleural effusion.18

Electrocardiography
ARVC is a disease characterized by ventricular arrhythmias1,2;
have infrequent VPCs in a 24-hour period. The presence of numerous VPCs (i.e., >100) or complex VPCs (e.g., couplets, triplets, bigeminy, runs of ventricular tachycardia) on a Holter monitor should be considered abnormal and strongly suggestive of ARVC.

**Echocardiography**

Although ARVC is best characterized by ventricular arrhythmias, it is a primary myocardial disease. However, the myocardial changes are most notable at the microscopic level, and most boxers with ARVC have normal echocardiographic findings. Only boxers with the myocardial dysfunction form of ARVC typically have echocardiographic abnormalities, which are seen as left ventricular dilation and systolic dysfunction. Although technically difficult, careful examination of the right ventricle in these cases may identify enlargement. In one study, echocardiographic assessment of right ventricular structure and function did not provide prognostic information.

**Magnetic Resonance Imaging**

Although magnetic resonance imaging (MRI) is becoming a more common diagnostic tool in veterinary medicine, motion artifacts have hindered its routine use for cardiac imaging. Basso et al used MRI postmortem to document fatty replacement within the right ventricle of ARVC-affected boxers. A recent study using MRI antemortem did not find such morphologic changes, although there was abnormal right ventricular function in boxers with ARVC compared with controls. Further studies of antemortem imaging may help define how MRI could be used as a noninvasive diagnostic tool.

**Histopathology**

ARVC is a primary myocardial disease characterized histologically by fatty or fibrofatty replacement of cardiac myocytes in the right, and sometimes left, ventricle (FIGURES 3 and 4). In human medicine, evidence of fibrofatty replacement on endomyocardial biopsy is considered a major diagnostic criterion. Endomyocardial biopsies are not routinely performed in veterinary medicine, but histopathology can be useful at necropsy for postmortem diagnosis in cases of sudden death of a previously healthy boxer.

**Genetic Testing**

Meurs et al recently identified an eight–base pair deletion within the striatin gene that was highly associated with disease status in ARVC-affected boxers and was not identified in unaffected boxers or other breeds of dogs tested. Affected boxers were either homozygous or heterozygous for the mutation, and homozygous dogs had a higher number of VPCs per 24 hours than heterozygous dogs. Testing for this genetic mutation is commercially available, and information can be found through the Washington State University website (www.vetmed.wsu.edu/deptSVCGL/Boxer/test.aspx).

**Screening in Asymptomatic Breeding Dogs**

With evidence of the familial nature of ARVC, there is a
strong interest in screening boxers that are to be used in breeding programs. Before the development of the readily available genetic test, annual Holter monitoring was the only test that could be recommended for screening these dogs. Although not based on long-term studies, a screening system was proposed by Meurs based on the prevalence of arrhythmias in the asymptomatic population (TABLE 1).

Before a genetic test was available, studies tried to develop other screening methods to identify the presence or severity of ARVC in boxers. Although QT dispersion may be an indicator of a re-entrant mechanism for arrhythmia, values did not correlate with disease severity in boxers with ARVC. Unlike humans with ARVC, plasma brain natriuretic peptide concentrations were not increased in boxers with ARVC. Signal-averaged ECG, used to detect abnormal conduction, has shown some usefulness in identifying ARVC-affected boxers that are more likely to die from cardiac-related causes. However, further study is needed to determine its clinical utility. A recent study has shown that the serum concentration of cardiac troponin I is higher in ARVC-affected boxers and that there is a positive correlation with the number of VPCs. Although this shows promise for a new diagnostic test, it should be noted that overlap existed between values for healthy and affected boxers. Further study is needed to clarify the clinical utility of this test in individual patients.

The identification of a genetic mutation associated with affected boxers and the commercial availability of a genetic test offers a new method of screening in asymptomatic breeding dogs. However, Holter monitoring still has a place in initial screening and annual monitoring of affected boxers due to incomplete genetic penetrance of the mutation (not all dogs positive for the mutation are clinically affected) and in determining whether therapy should be instituted.

**TABLE 1** Classification of ARVC Severity Based on Ventricular Premature Complexes

<table>
<thead>
<tr>
<th>VPCs Over 24 Hours</th>
<th>Possible Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–20 single</td>
<td>Within normal limits</td>
</tr>
<tr>
<td>20–100 single</td>
<td>Indeterminate; repeat in 6–12 months</td>
</tr>
<tr>
<td>100–300 single</td>
<td>Suspicious; no breeding for 1 year, then repeat</td>
</tr>
<tr>
<td>100–300 with increased complexity or 300–1000 single</td>
<td>Likely affected</td>
</tr>
<tr>
<td>&gt;1000 single</td>
<td>Affected; consider treatment</td>
</tr>
</tbody>
</table>

**Treatment and Prognosis**

Treatment for boxers with ARVC generally consists of only antiarrhythmic agents, unless there is evidence of systolic dysfunction and/or CHF (BOX 2). Although antiarrhythmic treatment has been shown to decrease VPC frequency and complexity, as well as the number of syncopal episodes, there is no evidence that treatment affects long-term survival or risk of sudden death. Additionally, treatment is not benign; antiarrhythmic agents may have a proarrhythmic effect.

**Asymptomatic Dogs**

Without evidence that treatment affects survival or the risk of sudden death, the benefit of treating asymptomatic dogs is uncertain. A firm relationship between the number of VPCs and the onset of clinical signs has not been established. Meurs et al found that dogs with syncope had more VPCs per 24 hours and more complex arrhythmias than control dogs, suggesting a causative relationship. However, significant variability existed, with some asymptomatic boxers having highly complex arrhythmias and thousands of VPCs per 24 hours. Therefore, it has been suggested that it may be reasonable to begin treatment in asymptomatic boxers that have ≥1000 VPCs per 24 hours, runs of ventricular tachycardia, or evidence of the R-on-T phenomenon. Ultimately, the decision to treat an asymptomatic dog should be approached on a case-by-case basis with the risks of...
Treatment in mind, taking into account all diagnostic information and the family history (if known).

**Syncope/Exercise Intolerance**
Treatment is typically initiated for boxers with clinical signs of syncope or exercise intolerance due to ventricular arrhythmias. Two protocols have been shown to be well tolerated and to decrease VPC frequency and complexity: (1) sotalol, 1.5 to 3.5 mg/kg PO q12h, and (2) the combination of mexiletine, 5 to 8 mg/kg PO q8h, and atenolol, 0.3 to 0.6 mg/kg PO q12h.37 Pretreatment Holter monitoring should be conducted, unless delaying initial treatment for 24 hours would not be in the best interest of the patient. Holter monitoring should also be conducted 2 to 4 weeks after treatment to assess response. Because there is great daily variability in VPC frequency among ARVC-affected boxers,41 a decrease in VPC frequency >80% should be achieved for therapy to be considered successful.

A recent study compared the standard sotalol dosage (1.5 to 3.5 mg/kg PO q12h) with therapy combining sotalol (1.5 to 3.5 mg/kg PO q12h) and mexiletine (5 to 7.5 mg/kg PO q8h).38 Although the combination therapy significantly decreased VPC number and arrhythmia complexity in more dogs, it showed no advantage over sotalol alone in decreasing episodes of syncope.38

**Myocardial Dysfunction and Congestive Heart Failure**
Boxers with the myocardial dysfunction form of ARVC may benefit from the treatment protocol for dilated cardiomyopathy in addition to antiarrhythmic therapy. A family of boxers that was found to have a deficiency in myocardial l-carnitine demonstrated improved systolic function after supplementation.41 Although this deficiency is not thought to be the underlying cause of ARVC in most boxers, supplementation with l-carnitine (50 mg/kg PO q8–12h) can be considered. Boxers that initially present with CHF should be stabilized and then evaluated for evidence of ARVC. The presence of ventricular arrhythmias would indicate the need for antiarrhythmic therapy in addition to CHF treatment.

**Recent Therapeutic Advancements**
Although the optimal dose and duration of treatment still remain to be elucidated, a recent study has shown that supplementation with omega-3 fatty acids resulted in a decreased VPC frequency in asymptomatic boxers with >95 VPCs per 24 hours.42 The dogs in this study received 780 mg of eicosapentaenoic acid and 497 mg of docosahexaenoic acid per day for 6 weeks. The effect on mortality was not evaluated.

The first treatment of a boxer with ARVC using an implantable cardioverter–defibrillator was reported in 2006.43 While this is not currently a routine therapeutic option for veterinary patients, it may become more available with further device advancement and study.

**Prognosis**
Many boxers can be managed using antiarrhythmic agents without recurrence of clinical signs for months to years.2,26 However, all dogs with ARVC are at risk for sudden death, with or without treatment. If the disease presents as or progresses to CHF, the prognosis becomes much more guarded.

**Conclusion**
Although treatment of symptomatic boxers with ARVC has not been shown to affect survival, it can decrease clinical signs and improve quality of life. In addition, it is hoped that increasing awareness of ARVC, its genetic origin, and

---

**BOX 2**

**Treatment Recommendations for Dogs With ARVC**

**Asymptomatic**
- No clear recommendations
- May be reasonable to treat if >1000 VPCs/24 h
- Treatment is not benign; approach case by case with family history in mind

**Syncope/exercise intolerance**
- One of the following protocols:
  - Sotalol (1.5–3.5 mg/kg PO q12h)
  - Mexiletine (5–8 mg/kg PO q8h) and atenolol (0.3–0.6 mg/kg PO q12h)
- Sotalol (1.5–3.5 mg/kg PO q2h) and mexiletine (5–7.5 mg/kg PO q8h)
- With all protocols:
  - Pretreatment Holter if patient stable enough to delay treatment 24 h
  - Posttreatment Holter at 2–4 weeks; therapy is considered successful when 80% decrease in VPC frequency is achieved

**Myocardial dysfunction/CHF**
- Stabilize if initially in CHF, then evaluate for evidence of ARVC
- Antiarrhythmic therapy as described above
- Treatment protocol as for dilated cardiomyopathy may benefit
- l-Carnitine supplementation may be considered (50 mg/kg PO q8–12h)

**ARVC** = arrhythmogenic right ventricular cardiomyopathy; **CHF** = congestive heart failure; **VPCs** = ventricular premature complexes.

<table>
<thead>
<tr>
<th>Treatment Recommendations for Dogs With ARVC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asymptomatic</strong></td>
</tr>
<tr>
<td>• No clear recommendations</td>
</tr>
<tr>
<td>• May be reasonable to treat if &gt;1000 VPCs/24 h</td>
</tr>
<tr>
<td>• Treatment is not benign; approach case by case with family history in mind</td>
</tr>
<tr>
<td><strong>Syncope/exercise intolerance</strong></td>
</tr>
<tr>
<td>• One of the following protocols:</td>
</tr>
<tr>
<td>- Sotalol (1.5–3.5 mg/kg PO q12h)</td>
</tr>
<tr>
<td>- Mexiletine (5–8 mg/kg PO q8h) and atenolol (0.3–0.6 mg/kg PO q12h)</td>
</tr>
<tr>
<td>- Sotalol (1.5–3.5 mg/kg PO q2h) and mexiletine (5–7.5 mg/kg PO q8h)</td>
</tr>
<tr>
<td>• With all protocols:</td>
</tr>
<tr>
<td>- Pretreatment Holter if patient stable enough to delay treatment 24 h</td>
</tr>
<tr>
<td>- Posttreatment Holter at 2–4 weeks; therapy is considered successful when 80% decrease in VPC frequency is achieved</td>
</tr>
<tr>
<td><strong>Myocardial dysfunction/CHF</strong></td>
</tr>
<tr>
<td>• Stabilize if initially in CHF, then evaluate for evidence of ARVC</td>
</tr>
<tr>
<td>• Antiarrhythmic therapy as described above</td>
</tr>
<tr>
<td>• Treatment protocol as for dilated cardiomyopathy may benefit</td>
</tr>
<tr>
<td>• l-Carnitine supplementation may be considered (50 mg/kg PO q8–12h)</td>
</tr>
</tbody>
</table>

ARVC = arrhythmogenic right ventricular cardiomyopathy; CHF = congestive heart failure; VPCs = ventricular premature complexes.
the availability of genetic testing will bring more breeders to exert active control over its propagation.

References
1. Which statement regarding the etiology of ARVC in boxers is correct?
   a. ARVC is caused by a mutation of one of the genes encoding desmoplakin.
   b. ARVC is not a familial disease.
   c. ARVC is an X-linked recessive trait.
   d. ARVC is inherited as an autosomal dominant trait with variable penetrance.

2. Which statement regarding ARVC is correct?
   a. ARVC is a primary myocardial disease.
   b. ARVC is caused by a primary conduction system abnormality.
   c. Most boxers with ARVC present similarly to Doberman pinschers with dilated cardiomyopathy.
   d. ARVC is an acquired disease.

3. The physical findings in most boxers with ARVC are typically
   a. normal.
   b. consistent with CHF.
   c. unremarkable except for the consistent finding of a left basilar systolic heart murmur.
   d. unremarkable except for the consistent finding of an S3 gallop.

4. Boxers with ARVC most commonly have VPCs that are described as having __________ morphology.
   a. AV block
   b. right bundle branch block
   c. left bundle branch block
   d. anterior fascicular block

5. Which statement regarding ECG findings in boxers with ARVC is correct?
   a. 24-hour Holter monitoring is rarely indicated in the diagnosis of ARVC.
   b. In-house ECG is less sensitive than 24-hour Holter monitoring.
   c. A definitive diagnosis of ARVC can be made with ECG alone.
   d. ECG is not important in the diagnosis of ARVC.

6. Which statement regarding the echocardiographic findings in boxers with ARVC is correct?
   a. Most affected dogs have systolic dysfunction.
   b. Most affected dogs have ventricular dilation.
   c. Most affected dogs have atrial enlargement.
   d. Most affected dogs have normal echocardiographic findings.

7. Which statement regarding the importance of histopathology in the diagnosis of ARVC is correct?
   a. Histopathology is important because antemortem endomyocardial biopsies are now routinely performed.
   b. Histopathology can be useful in postmortem diagnosis, especially in cases of sudden death.
   c. A regular muscle biopsy will show changes similar to cardiac muscle changes.
   d. Histopathology is not important in the diagnosis of ARVC.

8. Which statement regarding antiarrhythmic therapy in ARVC is correct?
   a. There is no risk of proarrhythmic effects when administering antiarrhythmic drugs.
   b. Atenolol alone is the treatment of choice.
   c. Sotalol alone is well tolerated and efficacious.
   d. Mexiletine should never be used in the treatment of ARVC.

9. A decrease in VPC frequency of __________ indicates successful antiarrhythmic therapy
   a. ≥25%
   b. ≥30%
   c. ≥50%
   d. ≥80%

10. Which finding is associated with a greater number of VPCs per 24 hours?
    a. increased QT dispersion
    b. increased serum concentration of brain natriuretic peptide
    c. homozygous status for genetic mutation associated with ARVC
    d. heterozygous status for genetic mutation associated with ARVC